Whether Entrectinib has been included in medical insurance and interpretation of related policies

Entrectinib is a new oral multi-target tyrosine kinase inhibitor, mainly targeting patients with solid tumors harboring ROS1, NTRK and ALK fusion mutations. It is suitable for the precise treatment of a variety of advanced or metastatic tumors. In recent years, with the promotion of the concept of precision medicine, the demand for clinical application of entrectinib in China has continued to rise. It is worth noting that entrectinib has been officially launched in China and has been included in the national medical insurance directory, which has reduced the financial burden for the majority of patients and provided a more stable treatment guarantee.

According to the current medical insurance policy, after entrectinib was included in the medical insurance catalog, the price has been significantly reduced compared with the initial stage of listing. The current price of the original drug in the domestic market is about 20,000 yuan per box (the specifications may be 100 mg Under normal circumstances, medical insurance patients can enjoy varying degrees of medical insurance reimbursement when purchasing via oncology prescriptions from secondary or tertiary hospitals, which greatly lowers the threshold for drug use.

For patients who cannot afford the price of the original drug for a long time, there is also a Laotian version of the generic drug on the market. It is understood that the generic version of entrectinib produced by Lucius Pharmaceutical Factory in Laos has a specification of 100 mg × 60 tablets and sells for only more than 1,000 yuan. Although it is a generic drug, its ingredients are basically the same as the original drug, and its efficacy and safety have also received positive feedback from many patients in clinical use. However, when choosing overseas channels, patients should pay attention to the legal compliance of drug sources to ensure the safety of drug purchases.

Overall, the inclusion of entrectinib in medical insurance marks its increasing clinical value and market recognition. In the future, with the popularization of genetic testing and the refinement of targeted treatment strategies, entrectinib is expected to play a role in the treatment of more solid tumors. At the same time, patients should scientifically choose original drugs or generic drugs based on their own economic conditions, medical insurance reimbursement status, and doctor's recommendations to achieve individualized and sustainable treatment goals.

Reference materials:https://www.drugs.com